Understand the source comparison
Doctors Prescribe Peptides Off Label: Comparison
GLP-1 Agonists (semaglutide, tirzepatide) Type 2 diabetes, obesity (Wegovy only) Metabolic dysfunction, NAFLD, cardiovascular risk reduction GLP-1 receptors in hepatic tissue regulate lipid metabolism and insulin sensitivity beyond glycemic control alone Basel
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Agonists (semaglutide, tirzepatide)
- Type 2 diabetes, obesity (Wegovy only)
- Metabolic dysfunction, NAFLD, cardiovascular risk reduction
- GLP-1 receptors in hepatic tissue regulate lipid metabolism and insulin sensitivity beyond glycemic control alone
- Baseline liver enzymes, lipid panel, documented metabolic syndrome criteria
- Strong mechanistic support. Hepatic GLP-1 receptor density justifies NAFLD application even without formal approval
- Growth Hormone Secretagogues (MK 677)
- None (investigational status in U.S.)
- Age-related muscle loss, sleep disorders, bone density maintenance
- Ghrelin receptor agonism increases endogenous GH pulse frequency and IGF-1, stimulating muscle protein synthesis and stage 3/4 sleep
- Baseline IGF-1, DEXA scan, polysomnography if sleep-focused
- Moderate support. Mechanism clear, but long-term safety data limited outside research settings
- Nootropic Peptides (Cerebrolysin, Dihexa)
- Stroke recovery (Cerebrolysin in select countries)
- Cognitive decline, traumatic brain injury, neurodegenerative disease
- BDNF upregulation and synaptic plasticity enhancement through neurotrophic signaling
- Baseline cognitive testing (MoCA or equivalent), documented progressive decline
- Emerging evidence. Cerebrolysin has RCT support in stroke; Dihexa remains investigational with limited human data
- Immune Modulators (Thymalin)
- None (research use in Russia)
- Immune senescence, autoimmune flare prevention, post-viral fatigue
- Thymic peptide restoration enhances T-cell differentiation and regulatory T-cell function
- Baseline immunoglobulin levels, T-cell subset panel, documented immune dysfunction
- Weak formal evidence. Mechanistic rationale exists but lacks robust Phase 3 data in Western literature